Prevalence of and Factors Associated with Financial Toxicity After Pancreatectomy and Gastrectomy

• Published in: Annals of surgical oncology 2024-07, Vol.31 (7), p.4361-4370
• Main Authors: Hirata, Yuki, To, Connie, Lyu, Heather, Smith, Grace L., Samuel, Joyce P., Tran Cao, Hop S., Badgwell, Brian D., Katz, Matthew H. G., Ikoma, Naruhiko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cancer therapies; Credit scoring; Cross-Sectional Studies; Female; Financial Stress - epidemiology; Financial Stress - etiology; Follow-Up Studies; Gastrectomy; Gastrectomy - adverse effects; Gastrectomy - economics; Gastrointestinal cancer; Gastrointestinal surgery; Global Health Services Research; Health Care Costs; Humans; Length of Stay - economics; Length of Stay - statistics & numerical data; Male; Medicine; Medicine & Public Health; Middle Aged; Minimally invasive surgery; Oncology; Pancreatectomy; Pancreatectomy - adverse effects; Pancreatectomy - economics; Pancreatic Neoplasms - surgery; Patients; Prevalence; Prognosis; Recovery of function; Stomach Neoplasms - pathology; Stomach Neoplasms - surgery; Surgery; Surgical Oncology; Surveys; Toxicity
• ISSN: 1068-9265; 1534-4681; 1534-4681
• DOI: 10.1245/s10434-024-15236-6

Background Financial toxicity (FT) refers to the adverse impact of cancer treatment costs on patients’ experiences, potentially leading to poor adherence to treatment and outcomes. However, the prevalence of FT among patients undergoing major upper gastrointestinal cancer operations, as well as factors associated with FT, remain unclear. Methods We conducted a cross-sectional study by sending the Comprehensive Score for financial Toxicity (COST) survey and Surgery-Q (a survey specifically developed for this study) to patients who underwent gastrectomy or pancreatectomy for malignant disease at our institution in 2019–2021. Results We sent the surveys to 627 patients and received responses from 101 (16%) patients. The FT prevalence (COST score